TLT.V - Theralase Technologies Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.2650
0.0000 (0.00%)
At close: 3:58PM EST
Stock chart is not supported by your current browser
Previous Close0.2650
Open0.2700
Bid0.2650 x 0
Ask0.2700 x 0
Day's Range0.2600 - 0.2700
52 Week Range0.2000 - 0.6000
Volume234,100
Avg. Volume347,393
Market Cap54.133M
Beta (5Y Monthly)1.31
PE Ratio (TTM)N/A
EPS (TTM)-0.0360
Earnings DateApr. 14, 2020 - Apr. 19, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.80
  • ACCESSWIRE

    Theralase Technologies Awarded 2020 TSX Venture 50

    TORONTO, ON / ACCESSWIRE / February 20, 2020 / Theralase ® Technologies Inc. (" Theralase " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company ...

  • Baystreet

    Stocks in play: Theralase® Technologies Inc.

    Has been granted a U.S. Patent for Multiwavelength PhotoDynamic Therapy technology. The U.S. patent ...

  • ACCESSWIRE

    Theralase Granted US Patent for Multiwavelength Photodynamic Therapy

    TORONTO, ON / ACCESSWIRE / January 27, 2020 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ("PDC") and their associated drug formulations intended to safely and effectively destroy various cancers, is pleased to announce that the Company has been granted a U.S. Patent for Multiwavelength PhotoDynamic Therapy ("PDT") technology. The U.S. patent entitled "Apparatus and Method for Multiwavelength Photodynamic Therapy" allows Theralase to use various laser wavelengths in the activation of PhotoDynamic Compounds ("PDC") in cancerous tumours.

  • ACCESSWIRE

    Theralase Wins Precedent-Setting Lawsuit Against Anonymous Individuals for Posting Defamatory Comments Online

    TORONTO, ON / ACCESSWIRE / January 16, 2020 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TLT.V)(TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds ("PDCs") and their associated drug formulations intended to safely and effectively destroy various cancers, is pleased to announce that the Company has won a precedent-setting lawsuit against anonymous internet posters for defamatory comments. The libelous posts were defamatory not only to the Company, but also certain employees, specifically: Roger Dumoulin-White and Kristina Hachey on a personal level.

  • CNW Group

    View from the C-Suite: Shawn Shirazi, Chief Executive Officer, Theralase Technologies Inc., tells his company's story. Filmed on December 18, 2019

    View from the C-Suite: Shawn Shirazi, Chief Executive Officer, Theralase Technologies Inc., tells his company's story. Filmed on December 18, 2019

  • ACCESSWIRE

    Theralase Releases Quarterly Newsletter

    TORONTO, ON / ACCESSWIRE / January 7, 2020 / Theralase® Technologies Inc. (" Theralase " or the " Company ") ( TSXV: TLT ) ( OTCQB: TLTFF ), a clinical stage pharmaceutical company ...

  • ACCESSWIRE

    Theralase Releases Third Quarter 2019 Financial Results and Company Update

    TORONTO, ON / ACCESSWIRE / November 29, 2019 / Theralase ® Technologies Inc. (" Theralase " or " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company focused ...

  • ACCESSWIRE

    Theralase Researchers Receive Recognition for Recent Scientific Publications

    TORONTO, ON / ACCESSWIRE / November 27, 2019 / Theralase ® Technologies Inc. (" Theralase " or " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company focused ...

  • ACCESSWIRE

    Theralase Announces Leadership Transition

    TORONTO, ON / ACCESSWIRE / October 31, 2019 / Theralase ® Technologies Inc. (" Theralase " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated ...

  • ACCESSWIRE

    Theralase Granted European Patent for Anti-Cancer Photo Dynamic Compounds

    TORONTO, ONTARIO / ACCESSWIRE / October 22, 2019 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ("PDC") and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to announce that the Company has been granted a European Patent for their anti-cancer PDCs, which will issue in due course. The patent entitled, "Metal-Based Thiophene Photodynamic Compounds and Their Use" advances Theralase's intellectual property portfolio internationally strengthening the patent portfolio around the Anti-Cancer Technology ("ACT") platform.

  • We're Keeping An Eye On Theralase Technologies's (CVE:TLT) Cash Burn Rate
    Simply Wall St.

    We're Keeping An Eye On Theralase Technologies's (CVE:TLT) Cash Burn Rate

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • ACCESSWIRE

    London Health Sciences Centre Launches as Newest Clinical Study Site for Phase II Non-Muscle Invasive Bladder Cancer Clinical Study

    TORONTO, ON / ACCESSWIRE / October 7, 2019 / Theralase® Technologies Inc. (" Theralase " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated ...

  • ACCESSWIRE

    Theralase Files Investigational New Drug Application with the FDA

    TORONTO, ONTARIO / ACCESSWIRE / October 01, 2019 / Theralase ® Technologies Inc. (" Theralase " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company ...

  • ACCESSWIRE

    Patient Six Cancer-Free Eighteen Months After Single Anti-Cancer Treatment

    TORONTO, ON / ACCESSWIRE / September 30, 2019 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ("PDCs") and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to announce that patient six, enrolled and treated in the Phase Ib Non-Muscle Invasive Bladder Cancer ("NMIBC") Clinical Study ("Study"), has demonstrated no tumour recurrence, progression or presence of NMIBC disease at the 540 day clinical and cystoscopy assessment. Patient six has demonstrated no tumour recurrence, progression or presence of NMIBC disease at the 90, 180, 270, 360 and now 540 days post treatment clinical cystoscopy assessment and urine cytology, marking a new milestone for the Company.

  • ACCESSWIRE

    Theralase Grants Stock Options

    TORONTO, ON / ACCESSWIRE / September 16, 2019 / Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV:TLT) (OTCQB:TLTFF), a clinical stage biopharmaceutical company developing Anti-Cancer treatments with their light activated Photo Dynamic Compounds (“PDC”) and associated drug formulations, today announces the grant of stock options. The Company has granted an aggregate of 12,340,000 stock options to directors, officers, employees & advisory board members pursuant to the Company’s stock option plan.

  • ACCESSWIRE

    Theralase Annouces First Patient Treated in Phase II Non-Muscle Invasive Bladder Cancer Clinical Study

    TORONTO, ON / ACCESSWIRE / September 4, 2019 / Theralase ® Technologies Inc. (“ Theralase ” or the “ Company ”) ( TSXV:TLT ) ( OTCQB:TLTFF ), a clinical stage biopharmaceutical company developing Anti-Cancer ...

  • ACCESSWIRE

    Theralase Releases Second Quarter 2019 Financial Results and Company Update

    TORONTO, ON / ACCESSWIRE / August 29, 2019 / Theralase® Technologies Inc. (" Theralase " or " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated ...

  • Need To Know: Theralase Technologies Inc. (CVE:TLT) Insiders Have Been Buying Shares
    Simply Wall St.

    Need To Know: Theralase Technologies Inc. (CVE:TLT) Insiders Have Been Buying Shares

    It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...

  • ACCESSWIRE

    Theralase Announces Pricing Of Prospectus Offering

    TORONTO, ON / ACCESSWIRE / August 1, 2019 / Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers, is pleased to announce today the price of its marketed public offering previously announced on June 26, 2019 (the “Offering”). The Offering will be conducted at a price of $0.30 per unit of the Company (a “Unit”) for minimum gross proceeds of $7,500,000 and maximum gross proceeds of $15,000,000 (the “Offering”). Each Unit will be comprised of one common share of the Company (the “Common Shares”) and one common share purchase warrant (the “Warrants”).

  • ACCESSWIRE

    Patient Five Cancer-Free Eighteen Months After Single Anti-Cancer Treatment

    TORONTO, ON / ACCESSWIRE / July 31, 2019 / Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy various cancers reports that patient five, enrolled and treated in the Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study”), has demonstrated no tumour recurrence, progression or presence of NMIBC disease at the 540 day clinical and cystoscopy assessment. The Study’s purpose was to evaluate TLD-1433, Theralase’s lead PDC, for the primary endpoint of safety and tolerability, secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and exploratory endpoint of efficacy, primarily at 90 days and secondarily at 180 days post treatment.

  • ACCESSWIRE

    McGill University Health Centre Newest Clinical Study Site for Phase II Non-Muscle Invasive Bladder Cancer Clinical Study

    MUHC is one of the leading academic health centres in the world and attracts clinical and research expertise from around the world, assessing the latest in medical technology and training the next generation of medical professionals.

  • ACCESSWIRE

    Theralase Enrolls First Patient into Phase II Non-Muscle Invasive Bladder Cancer Clinical Study

    TORONTO, ON / ACCESSWIRE / July 29, 2019 / Theralase® Technologies Inc. (“Theralase” or the “Company”) (TLT: TSXV) (TLTFF: OTCQB), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds (“PDC”) and their associated drug formulations, intended to safely and effectively destroy various cancers, announced today that the first patient has been enrolled into its Phase II clinical study titled “Patients with Non-Muscle Invasive Bladder Cancer (“NMIBC”), who present with Carcinoma In-Situ (“CIS”), who are considered Bacillus Calmette Guérin (“BCG”) Unresponsive or are intolerant to BCG Therapy (“Phase II”)” at University Health Network (“UHN”) in Toronto. Phase II has been designed in compliance with FDA industry guidelines for BCG-unresponsive NMIBC (issued:February 2018) and defined by the FDA in a Pre-Investigational New Drug (“IND”) conference call in late June 2019.

  • ACCESSWIRE

    Theralase Signs Agreement with Urology Organization to Provide US Clinical Study Sites for its Phase II Non Muscle Invasive Bladder Cancer Clinical Study

    TORONTO, ON / ACCESSWIRE / July 24, 2019 / Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers, is pleased to announce that the Company has signed an agreement with a Trial Management Organization (“TMO”) to provide 4 to 6 US based urology study sites that will be able to commence enrolling and treating patients, subject to Food and Drug Administration (“FDA”) Investigational New Drug (“IND”) approval for its Phase II Non Muscle Invasive Bladder Cancer (“NMIBC”) Clinical Study (“Study II”). The TMO is in discussions with approximately 14 potential US based clinical study sites that are large integrated clinical urology practices.